The latest from Spur

Explore our published results, updates, events, publications, and more

12.03.2024Press Release
Spur Therapeutics Announces Development Candidate in Parkinson’s Disease Gene Therapy Program
Read more
11.19.2024Press Release
Spur Therapeutics to Participate in Upcoming Investor Conferences
Read more
11.07.2024Press Release
Spur Therapeutics to Participate in B. Riley Securities’ Next-Gen Tissue Delivery Modalities Virtual Summit
Read more
10.31.2024Press Release
Spur Therapeutics Publishes Preclinical Proof-of-Concept Data for SBT101, its Gene Therapy Candidate in Adrenomyeloneuropathy (AMN)
Read more
10.23.2024Press Release
Spur Therapeutics Showcases Positive New Data from Phase 1/2 GALILEO-1 Trial of FLT201, Its Novel Gene Therapy Candidate for Gaucher Disease, in Oral Presentation at ESGCT 31st Annual Congress
Read more
10.23.2024Press Release
Spur’s ESGCT presentation on new clinical data for FLT201 in Gaucher Disease
Read more
10.03.2024Press Release
Spur Therapeutics Announces Oral Presentation Highlighting New Clinical Data for FLT201 in Gaucher Disease at Upcoming European Society of Gene & Cell Therapy (ESGCT) 31st Annual Congress
Read more
09.23.2024Press Release
Spur Therapeutics to Participate in Chardan’s 8th Annual Genetic Medicines Conference
Read more
07.08.2024Press Release
Spur Therapeutics Completes Enrollment in Phase 1/2 GALILEO-1 Trial of FLT201 in Gaucher Disease and Selects Dose for Planned Phase 3 Trial
Read more
Page 1 of 3

Explore earlier updates and announcements.

Stay up to date with news and updates from Spur

Show unsubscribe form